Discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results ...
The TBCRC-056 trial showed a 50% pCR rate in TNBC patients with BRCA or PALB2 mutations treated with niraparib and dostarlimab. sTILs increased significantly in both treatment arms, with higher ...
RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...
Real acupuncture significantly improves objective cognitive health in breast cancer survivors compared to sham acupuncture and usual care. Both real and sham acupuncture exceed the minimum clinically ...
Liquid biopsy using circulating tumor DNA (ctDNA) is emerging as a valuable tool in early-stage NSCLC, with the potential to ...
In this installment of The OncoloGIST, Hans Lee, MD, director of Myeloma Research at Sarah Cannon Research Institute, ...
Nadunolimab combined with chemotherapy showed no significant efficacy improvement in metastatic TNBC, despite surpassing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback